AU2017375949B2 - Protein kinase inhibitors - Google Patents
Protein kinase inhibitors Download PDFInfo
- Publication number
- AU2017375949B2 AU2017375949B2 AU2017375949A AU2017375949A AU2017375949B2 AU 2017375949 B2 AU2017375949 B2 AU 2017375949B2 AU 2017375949 A AU2017375949 A AU 2017375949A AU 2017375949 A AU2017375949 A AU 2017375949A AU 2017375949 B2 AU2017375949 B2 AU 2017375949B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- compounds
- alkoxyl
- independently hydrogen
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433410P | 2016-12-13 | 2016-12-13 | |
| US62/433,410 | 2016-12-13 | ||
| US201762539785P | 2017-08-01 | 2017-08-01 | |
| US62/539,785 | 2017-08-01 | ||
| PCT/US2017/065847 WO2018111893A1 (en) | 2016-12-13 | 2017-12-12 | Protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017375949A1 AU2017375949A1 (en) | 2019-05-23 |
| AU2017375949B2 true AU2017375949B2 (en) | 2021-09-09 |
Family
ID=61829613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017375949A Active AU2017375949B2 (en) | 2016-12-13 | 2017-12-12 | Protein kinase inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10479786B2 (enExample) |
| EP (1) | EP3555092A4 (enExample) |
| JP (1) | JP7077335B2 (enExample) |
| KR (1) | KR102582752B1 (enExample) |
| CN (1) | CN108473487B (enExample) |
| AU (1) | AU2017375949B2 (enExample) |
| CA (1) | CA3044066A1 (enExample) |
| WO (1) | WO2018111893A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10479786B2 (en) | 2016-12-13 | 2019-11-19 | Princeton Drug Discovery, Inc | Protein kinase inhibitors |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2020123277A1 (en) * | 2018-12-10 | 2020-06-18 | Princeton Drug Discovery Inc. | Protein kinase inhibitor prodrugs |
| KR102256804B1 (ko) * | 2019-02-26 | 2021-05-26 | 한국화학연구원 | N-페닐-2-(피리미딘-4-일아미노)티아졸-5-카복사미드 유도체, 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 미백 소재 조성물 |
| AU2021230289A1 (en) | 2020-03-03 | 2022-09-29 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| CA3229560A1 (en) | 2021-08-25 | 2023-03-02 | Christopher L. Vandeusen | Eif4e inhibitors and uses thereof |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040054186A1 (en) * | 1999-04-15 | 2004-03-18 | Jagabandhu Das | Cyclic protein tyrosine kinase inhibitors |
| WO2010144338A1 (en) * | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2308833A3 (en) | 1999-04-15 | 2011-09-28 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US20040209930A1 (en) * | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US20060021105A1 (en) * | 2004-07-29 | 2006-02-02 | Wilson Nick L | Ergonomic hand protection apparatus |
| PE20061394A1 (es) | 2005-03-15 | 2006-12-15 | Bristol Myers Squibb Co | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas |
| KR101433629B1 (ko) * | 2006-09-11 | 2014-08-27 | 쿠리스 인코퍼레이션 | 아연 결합 부분을 함유한 티로신 키나아제 억제제 |
| TW200906825A (en) | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| US20090076025A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched dasatinib |
| ES2396366T3 (es) | 2007-12-10 | 2013-02-21 | Concert Pharmaceuticals Inc. | Inhibidores heterocíclicos de quinasas |
| US8563554B2 (en) | 2009-03-17 | 2013-10-22 | Concert Pharmaceuticals, Inc. | Deuterated pyrazinoisoquinoline compounds |
| CA2775155A1 (en) * | 2009-10-01 | 2011-04-07 | Csl Limited | Method of treatment of philadelphia chromosome positive leukemia |
| CN101891738B (zh) | 2010-02-08 | 2011-09-28 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
| NZ717373A (en) | 2010-06-03 | 2017-11-24 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| EP2872159A2 (en) | 2012-07-13 | 2015-05-20 | Concert Pharmaceuticals Inc. | Deuterated carfilzomib |
| MX2015012610A (es) | 2013-03-14 | 2016-02-17 | Concert Pharmaceuticals Inc | Pacritinib deuterizado. |
| CN104130250B (zh) | 2013-05-07 | 2016-06-22 | 郑州泰基鸿诺药物科技有限公司 | 氘代达沙替尼及其制备方法和应用 |
| CN104151321B (zh) | 2013-05-15 | 2016-09-07 | 复旦大学 | N-(2-氯-6-甲基苯基)-2[(2-甲基嘧啶-4-基)氨基]噻唑-5-甲酰胺化合物及其制备方法和用途 |
| IL311537A (en) | 2014-01-28 | 2024-05-01 | Mayo Found Medical Education & Res | Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging |
| US20170224688A1 (en) | 2016-02-04 | 2017-08-10 | Acerta Pharma B.V. | Methods of Using BTK Inhibitors to Treat Dermatoses |
| WO2017168454A2 (en) * | 2016-04-02 | 2017-10-05 | Sun Pharma Advanced Research Company Limited | Novel compounds as btk inhibitors |
| US10479786B2 (en) * | 2016-12-13 | 2019-11-19 | Princeton Drug Discovery, Inc | Protein kinase inhibitors |
-
2017
- 2017-12-12 US US15/839,469 patent/US10479786B2/en active Active
- 2017-12-12 CN CN201780002746.8A patent/CN108473487B/zh active Active
- 2017-12-12 KR KR1020197018970A patent/KR102582752B1/ko active Active
- 2017-12-12 US US15/839,332 patent/US10174018B2/en active Active
- 2017-12-12 JP JP2019551918A patent/JP7077335B2/ja active Active
- 2017-12-12 EP EP17879997.9A patent/EP3555092A4/en active Pending
- 2017-12-12 AU AU2017375949A patent/AU2017375949B2/en active Active
- 2017-12-12 CA CA3044066A patent/CA3044066A1/en active Pending
- 2017-12-12 US US15/839,534 patent/US20180099961A1/en not_active Abandoned
- 2017-12-12 WO PCT/US2017/065847 patent/WO2018111893A1/en not_active Ceased
-
2018
- 2018-11-02 US US16/179,174 patent/US10556897B2/en active Active
-
2019
- 2019-12-19 US US16/721,142 patent/US11236080B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040054186A1 (en) * | 1999-04-15 | 2004-03-18 | Jagabandhu Das | Cyclic protein tyrosine kinase inhibitors |
| WO2010144338A1 (en) * | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180099959A1 (en) | 2018-04-12 |
| KR20190091312A (ko) | 2019-08-05 |
| JP7077335B2 (ja) | 2022-05-30 |
| JP2020503376A (ja) | 2020-01-30 |
| KR102582752B1 (ko) | 2023-09-22 |
| US10556897B2 (en) | 2020-02-11 |
| US20180099961A1 (en) | 2018-04-12 |
| CN108473487A (zh) | 2018-08-31 |
| AU2017375949A1 (en) | 2019-05-23 |
| US10174018B2 (en) | 2019-01-08 |
| US20190071437A1 (en) | 2019-03-07 |
| US20200123148A1 (en) | 2020-04-23 |
| US11236080B2 (en) | 2022-02-01 |
| EP3555092A4 (en) | 2020-05-13 |
| CA3044066A1 (en) | 2018-06-21 |
| WO2018111893A1 (en) | 2018-06-21 |
| US10479786B2 (en) | 2019-11-19 |
| CN108473487B (zh) | 2021-08-03 |
| EP3555092A1 (en) | 2019-10-23 |
| US20180099960A1 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017375949B2 (en) | Protein kinase inhibitors | |
| US10596174B2 (en) | Pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| KR101297497B1 (ko) | 단백질 키나제 저해제 | |
| EP2493313B1 (en) | Kinase inhibitors | |
| CN103748096B (zh) | 作为蛋白激酶抑制剂的吡咯并嘧啶化合物 | |
| EP3490564A1 (en) | Macrocycle kinase inhibitors | |
| WO2017066193A1 (en) | Novel inhibitors of protein kinases | |
| US9586965B2 (en) | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases | |
| WO2021074251A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives and their use in the treatment of cancer | |
| CA3160150C (en) | Novel deuterium-substituted pyrimidine derivative and pharmaceutical composition comprising same | |
| KR20250041906A (ko) | Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물 | |
| HK1238243B (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| HK1238243A1 (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| HK1210471B (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| HK1159630B (en) | Protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |